AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01709708
Drug: Marcaine
RxNorm normalized name: Marcaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.
Trial: NCT01709708
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT00646581
Drug: Insulin (Humulin)
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 IU Intranasal Insulin will be administered once
Trial: NCT02205528
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
Trial: NCT03259594
Drug: 100 g of amino acids supplementation
RxNorm normalized name: L-a-Amino-g-methylthiobutyric acid
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous supplementation with 100 g of amino acids 2 day before laparoscopic deroofing.
Trial: NCT02833480
Drug: Fluticasone group
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02833480
Drug: Budesonide group
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02833480
Drug: Formoterol group
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04644016
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clofarabine
Trial: NCT04644016
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine
Trial: NCT04644016
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan per PK
Trial: NCT04644016
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
Trial: NCT02993029
Drug: 99Tc-MDP
RxNorm normalized name: (99Tc)pertechnetate
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
Trial: NCT03302065
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01224366
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01796665
Drug: Acanya Gel
RxNorm normalized name: Acanya
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01575925
Drug: 4 mg Oral POM + 40 mg Oral DEX
RxNorm normalized name: Dex
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04176718
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: predetermined dose, intravenously, at predetermined times per cycle
Trial: NCT01575925
Drug: 2 mg Oral POM + 40 mg Oral DEX
RxNorm normalized name: Dex
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00351507
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01707082
Drug: PF-06282999
RxNorm normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 10 mg, every 8 hours, 14 days
Trial: NCT01707082
Drug: PF-06282999
RxNorm normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 30 mg, every 8 hours, 14 days
Trial: NCT01707082
Drug: PF-06282999
RxNorm normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 100 mg, every 8 hours, 14 days
Trial: NCT01707082
Drug: PF-06282999
RxNorm normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 250 mg, every 8 hours, 14 days
Trial: NCT00278460
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days
Trial: NCT00278460
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.
Trial: NCT01205256
Drug: methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25mg/kg IV of racemic methadone at the induction of anesthesia.
Trial: NCT04176718
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: predetermined dose, intravenously, give 3 times per cycle
Trial: NCT04176718
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: predetermined dose, orally, daily per cycle
Trial: NCT00256308
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 70mg/m2 IV over 120 min once a week during radiation
Trial: NCT01707082
Drug: PF-06282999
RxNorm normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days
Trial: NCT01707082
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
Trial: NCT01707082
Drug: PF-06282999
RxNorm normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
Trial: NCT02640495
Drug: Intravenous Artesunate as part of standard medical practice
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous Artesunate 2.4 mg/kg
Trial: NCT03605914
Drug: Norco
RxNorm normalized name: Norco
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
Trial: NCT04176718
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: predetermined dose, orally, given 8 times per cycle
Trial: NCT02206685
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
Trial: NCT00868907
Drug: 35 mg risedronate DR tablet
RxNorm normalized name: risedronate 35 MG
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
Trial: NCT01392755
Drug: danoprevir
RxNorm normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral doses of danoprevir
Trial: NCT01392755
Drug: omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral doses of omeprazole
Trial: NCT01392755
Drug: ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral dose of ranitidine
Trial: NCT01392755
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral doses of ritonavir
Trial: NCT00868907
Drug: 35 mg risedronate DR tablet
RxNorm normalized name: risedronate 35 MG
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
Trial: NCT00868907
Drug: 35 mg risedronate DR tablet
RxNorm normalized name: risedronate 35 MG
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
Trial: NCT03299387
Drug: Nitrofurantoin
RxNorm normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive oral Nitrofurantoin 100 mg twice daily for 7 days
Trial: NCT00072475
Drug: vatalanib
RxNorm normalized name: Vatalanib
DrugBank: Vatalanib (DB04879)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or \> tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
Trial: NCT04296162
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine chemotherapy (oral)
Trial: NCT04296162
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab target therapy
Trial: NCT01620762
Drug: Cat-PAD
RxNorm normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose every 4 weeks
Trial: NCT00304811
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00304811
Drug: Vancomycin plus Rifampin
RxNorm normalized name: Rifampin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02949271
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01460381
Drug: Quinidine
RxNorm normalized name: Quinidine
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04074551
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan
Trial: NCT04074551
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine
Trial: NCT04074551
Drug: Rosuvastatin and Ezetimibe
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin and Ezetimibe
Trial: NCT00797862
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.
Trial: NCT00797862
Drug: hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg capsules were taken orally once daily
Trial: NCT00797862
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.
Trial: NCT00531479
Drug: voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
Trial: NCT00531479
Drug: anidulafungin
RxNorm normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
Trial: NCT00531479
Drug: voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
Trial: NCT03521479
Drug: Squaric Acid Dibutyl Ester
RxNorm normalized name: Squaric acid dibutyl ester
DrugBank: Squaric acid dibutyl ester (DB12223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
Trial: NCT02711007
Drug: apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.
Trial: NCT02627625
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 inhalations
Trial: NCT00823901
Drug: Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
Trial: NCT03640221
Drug: Ertugliflozin
RxNorm normalized name: Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The sodium-glucose cotransporter 2 (SGLT2) inhibitors are an exciting new class of antidiabetic drugs that cause a modest reduction in high blood pressure and large reductions in the risk of cardiovascular disease (CVD) outcomes and renal outcomes in patients with advanced type 2 diabetes and very high CVD risk. However, the mechanistic underpinning of these CVD benefits is not well understood. this arm will allow us to test our hypothesis.
Trial: NCT01893320
Drug: Vosaroxin
RxNorm normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle.~Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I.
Trial: NCT01893320
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
Trial: NCT04322422
Drug: Inhaled corticosteriod/long-acting beta-agonist plus Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma; Montelukast is benefitial for allergic disease
Trial: NCT02174211
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of ranibizumab
Trial: NCT02174211
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of aflibercept
Trial: NCT00713739
Drug: Alfuzosin
RxNorm normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
Trial: NCT00713739
Drug: nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
Trial: NCT00713739
Drug: doxazosin
RxNorm normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
Trial: NCT02031289
Drug: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).~Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.~Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po.
Trial: NCT00713739
Drug: prazosin
RxNorm normalized name: Prazosin
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
Trial: NCT00316784
Drug: IDEA-033 (and rescue medication)
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01841827
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02304822
Drug: Multiple-dose of Ciprofloxacin prophylaxis
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
Trial: NCT02304822
Drug: Single-dose of Ciprofloxacin prophylaxis
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only.
Trial: NCT02304822
Drug: Zero-dose of Ciprofloxacin prophylaxis
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
Trial: NCT00618280
Drug: nicotine nasal spray
RxNorm normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,5 mg nicotine nasal spray or placebo (pepperspray)
Trial: NCT02256787
Drug: BILB 1941 ZW - single rising dose part
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02256787
Drug: BILB 1941 ZW - solution
RxNorm normalized name: Bilberry
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02256787
Drug: BILB 1941 ZW - tablet
RxNorm normalized name: Bilberry
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no